ORASURE TECHNOLOGIES INC: management transactions · United States · SEC (Form 4)

About ORASURE TECHNOLOGIES INC

OraSure Technologies Inc. (ticker: OSUR) is a U.S.-based healthcare diagnostics company listed on the NASDAQ in the United States. For French-speaking investors, the equity story sits at the intersection of point-of-care diagnostics, home testing, and sample collection/stabilization technologies. The company was founded in 1987 as SolarCare in Bethlehem, Pennsylvania, and later became OraSure Technologies in 2000 when it entered the public market. Its long operating history and regulatory know-how are part of its core investment appeal. ([orasure.com](https://orasure.com/company.html)) OraSure’s business is broadly organized around two pillars. First, it develops and commercializes rapid diagnostic tests, with the OraQuick platform being the most recognizable franchise. These products have historically covered infectious-disease screening such as HIV, hepatitis C, and syphilis, alongside other critical conditions and public-health applications. Second, the company sells sample collection and stabilization solutions used in molecular diagnostics, genomics research, microbiome studies, and pharmaceutical workflows. Its portfolio is designed to support multiple specimen types, including saliva, oral fluid, urine, skin cells, blood, and stool. That combination gives OraSure a differentiated position versus pure-play diagnostics peers. ([orasure.com](https://orasure.com/company.html)) From a competitive standpoint, OraSure is a niche player rather than a broad diversified medtech platform. Its strengths include a deep legacy in self-testing and point-of-need diagnostics, a recognized brand in certain infectious-disease categories, and a complementary sample-management franchise. At the same time, the company remains exposed to demand variability in public-health funding, changes in testing algorithms or reimbursement conditions, product adoption cycles, and competition from newer or lower-cost technologies. Management has emphasized regulatory execution, product innovation, and commercial channel expansion as key levers for future growth. ([orasure.gcs-web.com](https://orasure.gcs-web.com/news-releases/news-release-details/orasure-announces-fourth-quarter-2025-financial-results?utm_source=openai)) Recent developments matter for equity investors. In February 2026, OraSure said it expected to return to growth in 2026, supported by planned launches of a rapid molecular self-test for Chlamydia and Gonorrhoeae and its Colli-Pee™ at-home urine collection device for STI applications. In March 2025, the board authorized a $40 million share repurchase program over 24 months, funded from cash on hand, which signals confidence in the balance sheet and capital allocation discipline. The company also referenced a 2025 operational reset and ongoing efforts to stabilize demand and diversify its customer base. In short, OSUR is a NASDAQ-listed U.S. healthcare name with a focused diagnostics franchise, recurring regulatory catalysts, and meaningful execution risk. ([orasure.gcs-web.com](https://orasure.gcs-web.com/news-releases/news-release-details/orasure-announces-fourth-quarter-2025-financial-results?utm_source=openai))